Enhanced Antiparasitic Efficacy and Humoral Immune Modulation by Nitazoxanide-Loaded Chitosan Nanoparticles Against Experimental Cryptosporidiosis
Аннотация
Background Cryptosporidiosis is a leading cause of diarrheal disease worldwide and is particularly severe in immunocompromised individuals. Nitazoxanide (NTZ), the only FDA-approved therapy, shows limited effectiveness in this population. Chitosan nanoparticle (CS NP)-based delivery systems may enhance its therapeutic performance. This study evaluated NTZ, blank CS NPs, and NTZ-loaded CS NPs in immunocompetent and immunosuppressed mice experimentally infected with Cryptosporidium oocysts, by assessing mortality rate, fecal and intestinal oocyst counts, and ELISA-based serum IgM and IgG levels. Methods One hundred male Swiss albino mice were divided into five groups ( n = 20 each), each subdivided into immunocompetent and immunosuppressed subgroups ( n = 10). Group A served as uninfected, untreated controls; Group B comprised infected untreated mice; Groups C, D, and E received NTZ alone, blank CS NPs, and NTZ-loaded CS NPs. Results Mortality rate was lowest in the NTZ-loaded CS NP group (10% in immunocompetent; 30% in immunosuppressed mice). NTZ-loaded CS NPs achieved the greatest oocyst reductions: 73.5% and 67.1% in stool (day 20 PI), and 52.8% and 40.4% in intestinal contents (day 21 PI), in immunocompetent and immunosuppressed mice ( p < 0.001). Serum IgM and IgG were most substantially reduced in this group, a pattern consistent with reduced antigenic stimulation following treatment and offering correlative support for parasite clearance beyond oocyst counts alone. Conclusion Encapsulating NTZ in CS NPs significantly reduced fecal and intestinal oocyst burden and serum IgG relative to free NTZ, with a non-significant improvement in mortality. NTZ-loaded CS NPs represent a promising preclinical nanoparticle-based therapeutic strategy for cryptosporidiosis warranting optimization and evaluation.